- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00804037
Injection Snoreplasty: Comparison Between Ethanol and Ethanolamine Oleate
December 5, 2008 updated by: University of Sao Paulo
Injection Snoreplasty: Comparison Between Ethanol and Ethanolamine Oleate. A Randomized, Placebo-Controlled Study in Human Patients
SUMMARY INTRODUCTION: among various treatments for patients with primary snoring, upper airway resistance syndrome (UARS) and obstructive sleep apnea syndrome (OSAS), the injection snoreplasty arose as a promising alternative in some selected cases.
OBJECTIVE: to investigate the efficacy and tolerance of injection snoreplasty comparing Ethanol and Ethanolamine Oleate.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
SP
-
São Paulo, SP, Brazil
- University of Sao Paulo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Snoring
- RDI < 15 /h
Exclusion Criteria:
- BMI > 35
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Ethanol
|
Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)
|
Active Comparator: Ethanolamine Oleate
|
Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Snoring
Time Frame: 3 months after treatment
|
3 months after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Fabio TM Lorenzetti, MD, University of Sao Paulo
- Study Director: Michel B Cahali, PhD, University of Sao Paulo
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
December 5, 2008
First Submitted That Met QC Criteria
December 5, 2008
First Posted (Estimate)
December 8, 2008
Study Record Updates
Last Update Posted (Estimate)
December 8, 2008
Last Update Submitted That Met QC Criteria
December 5, 2008
Last Verified
November 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ORLHCFMUSP 1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Apnea
-
ResMedCRI-The Clinical Research Institute GmbH; University Hospital RegensburgCompletedObstructive Sleep Apnea | Central Sleep Apnea | Mixed Sleep Apnea | Complex Sleep ApneaSwitzerland, Spain, Denmark, Portugal, France, Germany
-
ResMedCompletedObstructive Sleep Apnea | Central Sleep Apnea (Diagnosis) | Chronic Opioid UseUnited States
-
LivaNovaRecruitingApnea | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | Apnea+Hypopnea | Apnea, Obstructive Sleep | Hypopnea, SleepUnited States
-
ResMedRWTH Aachen UniversityRecruitingObstructive Sleep Apnea | Central Sleep Apnea | Mixed Sleep ApneaGermany
-
Somnarus IncCompletedObstructive Sleep Apnea | Cheyne-Stokes Respiration | Central Sleep Apnea | Mixed Sleep ApneaUnited States
-
Mauro ManconiCompletedObstructive Sleep Apnea Syndrome | Sleep Apnea, Obstructive | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | OSAHSwitzerland
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
The Hospital for Sick ChildrenRecruitingObstructive Sleep Apnea | Hypoventilation | Central Sleep ApneaCanada
-
Medtronic - MITGCompletedObstructive Sleep Apnea | Sleep Apnea | Sleep-Disordered Breathing | Central Sleep ApneaUnited States
Clinical Trials on Injection Snoreplasty
-
Hospital de Clinicas de Porto AlegreUnknown
-
Medical University of South CarolinaCompletedSnoring | Obstructive Sleep ApneaUnited States
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
Royan InstituteCompletedMyocardial InfarctionIran, Islamic Republic of